Sotalol
Sotalol, sold as Betapace and Betapace AF, is a medicine taken by mouth that the US label describes as an antiarrhythmic, a medicine for heart rhythm problems, with both beta-blocking properties and properties that lengthen the heart's action potential. The label read, one label for the two brands, lists two uses: the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia (the label says it has not been shown to enhance survival in these patients); and keeping normal sinus rhythm, by delaying the recurrence of atrial fibrillation or flutter, in people with highly symptomatic episodes who are currently in sinus rhythm. It carries a boxed warning about life-threatening proarrhythmia, a drug-caused worsening of heart rhythm.
Also called Betapace · Betapace AF
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 9947 (sotalol); the label names the salt sotalol hydrochloride (RxNorm 7008, UNII HEC37C70XX, a broad match to the ingredient). MeSH descriptor D013015 is Sotalol. RxClass lists the FDA established pharmacologic class Antiarrhythmic (the page files under that class), a beta-receptor antagonist mechanism class and the physiologic effect Cardiac Rhythm Alteration. The label read is the Legacy Pharma USA, Inc. label for Betapace and Betapace AF, application NDA019865 in openFDA, effective 2024-12-16; Drugs@FDA lists Betapace AF under its own application NDA021151. Sotylize oral solution (NDA205108), Sorine and generic sotalol labels, and sotalol injection labels, were not read. This page records label indications, the class, the mechanism sentence and the title and first sentence of the boxed warning only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says sotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties.
Classification codes
-
HEC37C70XXSotalol hydrochloride
Claims and evidence
Context Patients taking sotalol, as described in a US Betapace and Betapace AF label boxed warning
- Recipient
- Recipient not specified
- Population
- Patients who take the medicine, as the boxed warning describes the risk. The passages read give no age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Patients taking Betapace or Betapace AF
- Excluded
- None stated
The same US label carries a boxed warning titled life-threatening proarrhythmia. It says the medicine can cause life-threatening ventricular tachycardia associated with QT interval prolongation.
Applies to Recipient not specified Patients taking sotalol, as described in a US Betapace and Betapace AF label boxed warning
- Certainty method
- Not assessed
- Limitations
- This claim records the title and first statement of the label's boxed warning only. The warning goes on to tell prescribers where treatment is started and what to do if the QT interval lengthens; those instructions are not repeated here. Other warnings, contraindications and interactions were not recorded. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].boxed_warning[0], title
- How it applies
- Label passage quoted in the research quote table (LB-10).
- Retrieved
- Source effective date
- 2024-12-16
- Source state
- Current
- Version fingerprint
c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].boxed_warning[0], first paragraph
- How it applies
- Label passage quoted in the research quote table (LB-11).
- Retrieved
- Source effective date
- 2024-12-16
- Source state
- Current
- Version fingerprint
c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20241216.
- Retrieved
- Source effective date
- 2024-12-16
- Source state
- Current
- Version fingerprint
c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Context Patients with life-threatening ventricular arrhythmias, or with highly symptomatic atrial fibrillation or flutter who are in sinus rhythm, as described in the US label of Betapace and Betapace AF
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label: patients with documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia, and patients with highly symptomatic atrial fibrillation or flutter who are currently in sinus rhythm. The passages read do not state an age range.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Patients with documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia
- Patients with highly symptomatic atrial fibrillation or flutter who are currently in sinus rhythm
- Excluded
- None stated
The US label of Betapace and Betapace AF (sotalol hydrochloride tablets, Legacy Pharma USA, Inc., application NDA019865; the version dated 2024-12-16 in openFDA) describes the medicine as an antiarrhythmic. It lists the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia, and the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) in patients with highly symptomatic atrial fibrillation or flutter who are currently in sinus rhythm. It states that the medicine has not been shown to enhance survival in patients with life-threatening ventricular arrhythmias.
Applies to Recipient not specified Patients with life-threatening ventricular arrhythmias, or with highly symptomatic atrial fibrillation or flutter who are in sinus rhythm, as described in the US label of Betapace and Betapace AF
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also gives limitations of use for the atrial fibrillation indication (reserve for highly symptomatic patients); those are the label's statements and are not repeated as advice. Contraindications, other warnings, the label's pediatric statements and dosing were not recorded. The oral solution (Sotylize) and generic labels were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (4)
-
- Locator
- results[0].indications_and_usage[0], indications statement
- How it applies
- Label passage quoted in the research quote table (LB-04).
- Retrieved
- Source effective date
- 2024-12-16
- Source state
- Current
- Version fingerprint
c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.1 Life-Threatening Ventricular Arrhythmias
- How it applies
- Label passage quoted in the research quote table (LB-05, LB-06).
- Retrieved
- Source effective date
- 2024-12-16
- Source state
- Current
- Version fingerprint
c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1.2 Delay in Recurrence of Atrial Fibrillation/Atrial Flutter (AFIB/AFL)
- How it applies
- Label passage quoted in the research quote table (LB-07, LB-08).
- Retrieved
- Source effective date
- 2024-12-16
- Source state
- Current
- Version fingerprint
c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20241216.
- Retrieved
- Source effective date
- 2024-12-16
- Source state
- Current
- Version fingerprint
c4c31394b7cf5fe34ca6f97586b4d494090f7a6f9d7e78ffe09e4a71549f1d00- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-18, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists treatment of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia, as an indication: Ventricular tachycardia
Applies to Recipient not specified Patients with life-threatening ventricular arrhythmias, or with highly symptomatic atrial fibrillation or flutter who are in sinus rhythm, as described in the US label of Betapace and Betapace AF
The US label of Betapace and Betapace AF (sotalol hydrochloride tablets, Legacy Pharma USA, Inc., application NDA019865; the version dated 2024-12-16 in openFDA) describes the medicine as an antiarrhythmic. It lists the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia, and the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) in patients with highly symptomatic atrial fibrillation or flutter who are currently in sinus rhythm. It states that the medicine has not been shown to enhance survival in patients with life-threatening ventricular arrhythmias.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also gives limitations of use for the atrial fibrillation indication (reserve for highly symptomatic patients); those are the label's statements and are not repeated as advice. Contraindications, other warnings, the label's pediatric statements and dosing were not recorded. The oral solution (Sotylize) and generic labels were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists keeping normal sinus rhythm, by delaying the recurrence of atrial fibrillation or flutter, in people with highly symptomatic episodes who are in sinus rhythm as an indication: Atrial fibrillation (AF)
Applies to Recipient not specified Patients with life-threatening ventricular arrhythmias, or with highly symptomatic atrial fibrillation or flutter who are in sinus rhythm, as described in the US label of Betapace and Betapace AF
The US label of Betapace and Betapace AF (sotalol hydrochloride tablets, Legacy Pharma USA, Inc., application NDA019865; the version dated 2024-12-16 in openFDA) describes the medicine as an antiarrhythmic. It lists the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia, and the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) in patients with highly symptomatic atrial fibrillation or flutter who are currently in sinus rhythm. It states that the medicine has not been shown to enhance survival in patients with life-threatening ventricular arrhythmias.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also gives limitations of use for the atrial fibrillation indication (reserve for highly symptomatic patients); those are the label's statements and are not repeated as advice. Contraindications, other warnings, the label's pediatric statements and dosing were not recorded. The oral solution (Sotylize) and generic labels were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
-
Claim, not a settled fact FDA label lists keeping normal sinus rhythm, by delaying the recurrence of atrial fibrillation or flutter, in people with highly symptomatic episodes who are in sinus rhythm as an indication: Atrial flutter
Applies to Recipient not specified Patients with life-threatening ventricular arrhythmias, or with highly symptomatic atrial fibrillation or flutter who are in sinus rhythm, as described in the US label of Betapace and Betapace AF
The US label of Betapace and Betapace AF (sotalol hydrochloride tablets, Legacy Pharma USA, Inc., application NDA019865; the version dated 2024-12-16 in openFDA) describes the medicine as an antiarrhythmic. It lists the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia, and the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation or flutter) in patients with highly symptomatic atrial fibrillation or flutter who are currently in sinus rhythm. It states that the medicine has not been shown to enhance survival in patients with life-threatening ventricular arrhythmias.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label also gives limitations of use for the atrial fibrillation indication (reserve for highly symptomatic patients); those are the label's statements and are not repeated as advice. Contraindications, other warnings, the label's pediatric statements and dosing were not recorded. The oral solution (Sotylize) and generic labels were not read. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Record details
- Record id
cardio:sotalol- Content hash
61ddc3b488b89f12cb4c6a6bbdaf8a89a1be478df909dddf25fc477fbe61566f